Merck &quot;good&quot; cholesterol drug meets trial goals
633683
Merck & Co&#39;s   combination pill to raise &quot;good&quot; HDL cholesterol with less  facial flushing -- a common side effect of HDL drugs -- met its  main goals in a late-stage test, researchers said on Sunday.
34206
Merck & Co.  on Wednesday stood by its forecast of flat earnings for 2006 and projected slightly higher 2007 results, in line with Wall Street expectations, as the drugmaker grapples with generic competition for a number of its medicines.
64799
Merck&#39;s (nyse: MRK - news - people ) decision is based on new three-year data from a clinical trial designed to test the effect of Vioxx on preventing colorectalpolyps.
125992
Merck has obtained rights to license an experimental anti-obesity drug that is based on a hormone the body uses to signal that it has eaten enough.
132631
NEW YORK - Inconclusive trial results for Merck&#39;s Zocor might turn out to be a boost for the company&#39;s next cholesterol medicine, Vytorin.
751523
A new addition to an already successful drug promises good results for investors.
455038
U.S. regulators said on Friday they would review whether to take action over Merck & Co Inc's and Schering-Plough Corp's popular cholesterol drug Vytorin after a study showed it was no better than a generic in preventing the build-up of fatty plaque.
310266
Trial results for a drug that controls bleeding include a favorable comparison with a similar product.
519863
The company faces a pivotal clinical trial.
584007
Investors reward the drugmaker for positive study results.
765930
U.S. regulators said on Friday they  would review a study showing a Merck and Schering-Plough  cholesterol drug worked no better than a generic in preventing  the build-up of arterial plaque.
384652
Drug maker Merck & Co. Inc. said on Friday it acted "responsibly and appropriately" in developing and marketing recently recalled arthritis drug Vioxx.
723523
A long-acting niacin drug that  raises so-called good cholesterol showed promise in slowing the  clogging of arteries when taken along with cholesterol-lowering  statins compared to statin therapy alone, according to a small  clinical study.
303689
Acorda announces positive clinical trial data.
768183
An experimental drug from Sanofi-Aventis, viewed as pivotal to the newly merged company's future, showed good results in the largest clinical study of the product to date.
566145
The companies will not change the main endpoint of a study of their cholesterol drugs Zetia and Vytorin.
263089
A Merck &amp; Co. Inc. drug received federal approval Friday to treat a slow-growing cancer that affects infection-fighting white blood cells.